Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD8 PET imaging with 89Zr-Df-crefmirlimab during anti-PD-1 therapy in metastatic solid tumors
NL-OMON59390Phase 2Recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Mar 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of [89Zr]Zr-Df-Crefmirlimab and nivolumab in Nonhematologic neoplasms, sponsored by University Medical Center Groningen. Primary endpoints: Whole-body biodistribution of 89Zr-Df-crefmirlimab, Pharmacokinetics of 89Zr-Df-crefmirlimab and 2 more. Started Mar 2025; status: recruiting.
02
Drugs
[89Zr]Zr-Df-Crefmirlimabnivolumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59390.